skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

医薬品・医療機器の国際展開を強力にサポート

Pink Sheet

薬事ニュース「Pink Sheet」とは?
「Pink Sheet」は、世界の薬事規制動向&情報に特化した有料購読ニュースです。医薬品・医療機器関連の国際展開に不可欠な最新情報を毎日、アナリストによる分析と共にお届けします。

配信トピック
米国食品医薬品局・欧州医薬品庁など各国薬事規制当局の最新動向、薬事規制、製造・販売の承認審査制度、医療政策、薬価政策、特許、保険政策、償還制度、市場アクセス、臨床試験の実施状況他

購読までの流れ
お申込み → ID発行 → ログインして閲覧

まずは実際の記事の見出しを「Pink Sheet」よりご確認ください。
※見出しは無料で見られます。

このサービスの特徴

無料の最新記事&レポート

  • 世界の薬事規制動向&情報を配信

    Moderna COVID-19 Vaccine: Booster Study Hits Only One Of Two Immunogenicity Endpoints

    13 Oct 2021

    PS2110_Bullseye_hit_miss_CPTYM3_1200

    Immune responses to a single booster dose of mRNA-1273 would be considered successfully bridged to the two-dose primary series if each of two immunobridging criteria were met, but the mRNA vaccine missed the prespecified success criteria for seroresponse rate, the FDA said.

  • 世界の薬事規制動向&情報を配信

    CureVac Pulls Covid Vaccine From European Review Process

    12 Oct 2021

    COVID19_vaccine_1200

    The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.

  • 世界の薬事規制動向&情報を配信

    AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

    16 Aug 2021

    PS2106_DRP_Fotivda_1200

    After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.

  • 世界の薬事規制動向&情報を配信

    Expectations Are High But What Precisely Will England’s New IMF Deliver?

    By Leela Barham 03 Aug 2021

    PS2108_Drug_Pricing_UK_EK0KWF_1200

    The Innovative Medicines Fund, due for launch in England later this year, may provide industry with an opportunity to hold key public bodies to account.

  • 世界の薬事規制動向&情報を配信

    Merck, Pfizer Pneumococcal Vaccines: More Serotype Protection Vs. Pneumonia Indication

    03 Aug 2021

    PS2108_pneumococcalvaccinesyringe_RRB6GX_1200

    Ahead of CDC advisory committee this fall, Merck highlights additional bacteria serotypes its Vaxneuvance protects against while Pfizer touts Prevnar 13’s indication for pneumonia.

  • 世界の薬事規制動向&情報を配信

    Global Regulatory Harmonization Discussions Ongoing About COVID-19 Vaccine Boosters

    14 Jul 2021

    Pfizercovidboostersgreenlightyellowlight

    US position remains that boosters are not needed yet, but CBER Director Peter Marks says regulators are discussing how to harmonize applications for booster shots.

  • 世界の薬事規制動向&情報を配信

    COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms

    30 Jun 2021

    PS2106_DELAYS_C67AWJ_1200

    A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.

  • 世界の薬事規制動向&情報を配信

    Woodcock Attributes Aduhelm Approval Controversy To ‘Process Problems’

    By M. Nielsen Hobbs 23 Jun 2021

    mt2105_fixingaproblem_D9T78X_1200

    US FDA’s approval after a near-unanimous advisory committee vote against Biogen’s Alzheimer’s drug is central to many critics’ arguments, but the acting commissioner says that panel did not vote on the issue of accelerated approval, and that airing of internal agency disagreements could have influenced committee members.

  • 世界の薬事規制動向&情報を配信

    US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion

    By Sarah Karlin-Smith 16 Jun 2021

    PS2106_emotionsonrocks_2A6FBP5_1200

    CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.

  • 世界の薬事規制動向&情報を配信

    Aducanumab Accelerated Approval Reflects US FDA Flexibility But Raises Doubts About Confirmatory Trial

    08 Jun 2021

    PS2106_Rabbit_in_hat_BJD1C2_1200

    Biogen/Eisai Alzheimer’s drug wins agency nod on basis of amyloid plaque reduction, a surprising use of the accelerated approval pathway that was not considered by an FDA advisory committee; approval raises feasibility questions about confirmatory trial and daunting prospect of market withdrawal if studies fail to verify clinical benefit.

  • 世界の薬事規制動向&情報を配信, Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Drug Pricing eBook

    25 May 2021

    Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

    Topic drug-pricing

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, 世界の薬事規制動向&情報を配信

    Manufacturing and Distribution: Challenges and Opportunities

    13 May 2021

    The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

    Topic strategy

  • 世界の薬事規制動向&情報を配信

    US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning

    By Sarah Karlin-Smith 06 May 2021

    JoeBidenwithIndianflaginbackground_1200-1306679316

    Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.

  • 世界の薬事規制動向&情報を配信

    Long-Awaited EU Clinical Trials Portal Meets Major Milestone

    22 Apr 2021

    PS2104_Complex_J4040N_1200

    A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.

  • 世界の薬事規制動向&情報を配信

    Sputnik V COVID-19 Vaccine Causing A Stir In The EU

    08 Apr 2021

    PS2104_SputnikV_vaccine_2DNKG2R_1200

    The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.

医薬品産業専門のジャーナリスト&アナリスト

Editor

Brenda Sandburg

Editor, Senior Editor

New York, USA

Brenda Sandburg

Brenda specializes in

  • Policy and Regulation
  • Biosimilars
  • Biotech
  • Generics
  • Pricing

39+ years of experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly
Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。